Newsbenzinga
Immix Biopharma Reports 89% Complete Response Rate In Interim Phase 2 Data For NXC-201 In AL Amyloidosis; Plans BLA Submission Mid-2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…